Coming soon: Acteev Biodefend™ antiviral and antibacterial technology
Print this page

Coming soon: Acteev Biodefend™ antiviral and antibacterial technology

DISCLAIMER: Acteev™ technology has been shown in laboratory tests to destroy SARS-CoV-2, the coronavirus that causes COVID-19, and other pathogens including H1N1, coronavirus 229E and Gram-positive and Gram-negative bacteria such as staphylococcus and E. coli. All data presented on this page comes from testing performed by independent third-party laboratories following the protocols of ISO, ASTM or other international standards organizations. Not all claims are permitted in all jurisdictions, including in the United States. Some device designs currently under review with the U.S. Food and Drug Administration — submission number K201714. Ascend has more than 15 patent families pending on Acteev technology.

Ascend files first FDA 510(k) submission based on Acteev technology

The medical device, a surgical mask under the Acteev Biodefend™ brand, is being reviewed by the U.S. Food and Drug Administration.

Read the press release

Achieve protection from pathogens while maintaining top filtration properties

Acteev Biodefend combines the same protections against microbes as Acteev Protect with the revolutionary power to deactivate viruses.
  • Flexibility to work with your designs while maintaining performance.​

  • Agile manufacturing model allows us to scale immediately to your requirements.​

How Acteev works: technology and efficacy

Acteev™ technology uses active zinc ions embedded within the polymer structure to deliver protection against viruses, bacteria and fungi. Ascend has partnered with world-renowned scientists and laboratories to analyze this cutting-edge technology.

See the data and test methods


Acteev Biodefend technology with its unique embedded Zn2+ ion shows a strong virucidal property against human corona virus 229E (over 99.9% efficacy) in line with fundamental molecular biology research. Further, this virucidal technology offers a potential to deactivate a broad spectrum of viruses causing Covid-19, influenza, measles, AIDS, common cold, to name but a few."
AJ te Velthuis, Ph.D., Sir Henry Dale Fellow, University of Cambridge Department of Pathology, Division of Virology
The specialty polyamide polymer matrix... shows superior and potentially class-leading antimicrobial efficacy against Escherichia coli, Staphylococcus aureus and Klebsiella pneumoniae when embedded with ionic zinc (Zn2+)…. The reported reduction in bacterial growth is greater than many competing functionalised surface materials, such as metal oxide nanoparticles..."
Christopher A. McDevitt, Ph.D., Associate Professor, ARC Future Fellow and Group Leader, University of Melbourne

Contact an Ascend expert to request a sample or learn more about our technology